Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-04-25
2006-04-25
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387900, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750, C530S391100, C530S391700, C530S395000, C424S133100, C424S141100, C424S144100, C424S152100, C424S153100, C424S154100
Reexamination Certificate
active
07034121
ABSTRACT:
The invention provides an antibody-toxic moiety conjugates comprising an antibody that specifically recognizes a molecule expressed on the surface of a T cell which is expressed only on T cells and is only expressed transiently on T cells upon T cell activation. Preferably, the T cell molecule is CTLA4. The invention further provides anti-CTLA4 antibodies and humanized forms thereof.
REFERENCES:
patent: 5773001 (1998-06-01), Hamann et al.
patent: 5821332 (1998-10-01), Godfrey et al.
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6207156 (2001-03-01), Kuchroo et al.
patent: 2002/0086014 (2002-07-01), Korman et al.
patent: WO 98/56417 (1998-12-01), None
Bendig Methods: A Companion to Methods in Enzymology 1995; 8:83-93.
Swiss-Prot #43489, TNR4—Human, Release 45, Sep. 2003.
Godfrey et al. J. Exp. Med. 1994; 180:757-762.
Colombatti, M. et al., “Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures,”J. Immunol., Dec. 1983;131(6):3091-5.
Duke-Cohan, J. S. et al., “Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26,”Blood, Oct. 1, 1993;82(7):2224-34.
Koehler, M. et al., “XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors,”Bone Marrow Transplant., May 1994; 13(5):571-5.
Razi-Wolf, Ziba et al., “Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor,”Proc. Nat. Acad. Sci. U.S.A., 90(23):11182-6 (1993).
Sievers, E.L. et al., “Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate,”BloodJun. 1, 1999;93(11):3678-84.
Vandenborre, K. et al., “Interaction of CTLA-4 (CD152) with CD80 or CD86 Inhibits human T-cell activation,”Immnunology, 98(3):413-421 (1999).
Carreno Beatriz M.
Collins Mary
Gray Gary S.
Hinton Paul R.
Morris Donna
Foley & Hoag LLP
Gambel Phillip
Genetics Institue, LLC
Ouspenski Ilia
LandOfFree
Antibodies against CTLA4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against CTLA4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against CTLA4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587629